ReviewBriefings in bioinformatics2026
Can autonomous Agentic-AI systems accelerate drug discovery and development in the next decade?
Review in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pharmaceutical industry is experiencing a profound transformation driven by rapid advancements in artificial intelligence (AI), increasing research and development complexity, and the expiration of key patents. Agentic-AI systems, which enable autonomous reasoning, decision-making, and adaptive learning beyond traditional data-driven automation, represent a paradigm shift in this context. This review examines the impact of Agentic-AI across the pharmaceutical value chain, including supply chain orchestration, manufacturing optimization, early-stage drug discovery, process development, and regulatory intelligence. These systems enhance operational resilience, reduce development timelines, and accelerate the identification of new therapeutic candidates by fostering dynamic human-AI collaboration. However, the widespread adoption of Agentic-AI introduces significant challenges related to workforce integration, ethical accountability, governance, and regulatory compliance. Addressing these challenges is essential for reliable and scalable deployment. This study identifies key factors shaping Agentic-AI's influence over the next decade and provides a forward-looking perspective on its evolving role in pharmaceutical innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.